Selexipag

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Selexipag
   1. Pharmacist Assessment Report
   2. Selexipag: Known uses and market status in India
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. India Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Selexipag: Known uses and market status in India

Summary

The TxGNN deep-learning model produced no candidate indication with a score of 0.99 or higher for Selexipag, so there is currently no new predicted indication. The drug’s own recorded uses are listed below. They are existing records, not model candidates.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	2
Evidence level	Not applicable
India Market Status	Listed in a compiled Indian medicine price dataset (4 of 4) – CDSCO approval status is not included in this data
Number of Listed Products	4 (valid: 4)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
pulmonary hypertension	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
pulmonary arterial hypertension

India Market Information

Licence	Product	Dosage form	Status
247714	Zexipag 400mcg Tablet	strip of 10 tablets	Valid
200368	Selepeg 200 Tablet	strip of 10 tablets	Valid
201099	Selepeg 400 Tablet	strip of 10 tablets	Valid
247209	Zexipag 200mcg Tablet	strip of 10 tablets	Valid

Safety Considerations

• Drug Interactions: 191 interactions were recorded. The 20 listed in the compiled data are all moderate severity, including:
  • SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin)
  • Vasoactive agents and sympathomimetics (epinephrine, ephedrine, phenylephrine, phentolamine, papaverine, amyl nitrite)
  • Others (mannitol, glycerin, amifostine, deferasirox, diazoxide, abiraterone, acebutolol)

Please refer to the package insert for warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---